PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19490202-4	2009	DISCUSSION: Thiazolidinediones attenuate circulating levels of pro-inflammatory mediators in patients with type 2 diabetes, including C-reactive protein, interleukin-6, CD40L, monocyte chemoattractant protein-1 and metalloproteinase-9.	Thiazolidinediones	12-30	C-reactive protein	Homo sapiens	134-152	
20926154-0	2010	The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.	Thiazolidinediones	15-33	C-reactive protein	Homo sapiens	49-67	
20926154-6	2010	Standard mean difference (SMD) of CRP and 95% CI were calculated to evaluate the effect of TZDs on CRP.	Thiazolidinediones	91-95	C-reactive protein	Homo sapiens	99-102	
20926154-9	2010	Moreover, TZDs were found to significantly reduce CRP levels in both diabetes mellitus (DM) and non-DM patients.	Thiazolidinediones	10-14	C-reactive protein	Homo sapiens	50-53	
16490432-0	2006	Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels.	Thiazolidinediones	31-49	C-reactive protein	Homo sapiens	59-77	
16490432-1	2006	We conducted a meta-analysis of randomized clinical trials to evaluate the effect of thiazolidinediones on serum C-reactive protein levels.	Thiazolidinediones	85-103	C-reactive protein	Homo sapiens	113-131	
16490432-2	2006	Compared with placebo, treatment with thiazolidinediones significantly decreased the serum C-reactive protein levels (mean -0.82 mg/L, 95% confidence interval -1.15 to -0.49 mg/L, p <0.0001).	Thiazolidinediones	38-56	C-reactive protein	Homo sapiens	91-109	
16490432-3	2006	In a subgroup analysis, the effect of thiazolidinediones on the serum C-reactive protein levels was more pronounced in diabetic patients (mean -1.24 mg/L, 95% confidence interval -2.15 to -0.32 mg/L, p = 0.008) compared with nondiabetic patients (mean -0.27 mg/L, 95% confidence interval -0.41 to -0.14 mg/L, p <0.0001).	Thiazolidinediones	38-56	C-reactive protein	Homo sapiens	70-88	
15459582-6	2004	TZDs decrease plasma insulin levels, improve endothelial function, decrease vascular inflammation, and decrease C-reactive protein levels, effects that are potentially beneficial in patients with heart failure.	Thiazolidinediones	0-4	C-reactive protein	Homo sapiens	112-130	
14742804-8	2004	Drugs including statins, fibrates, niacin, thiazolidinediones, and antiplatelet agents, as well as weight loss and exercise, have demonstrated efficacy in lowering CRP levels.	Thiazolidinediones	43-61	C-reactive protein	Homo sapiens	164-167	
15236798-3	2004	Strategies for decreasing elevated CRP include administration of statins, thiazolidinediones, and metformin; moderate alcohol consumption and appropriate weight loss are also helpful in this regard.	Thiazolidinediones	74-92	C-reactive protein	Homo sapiens	35-38	
12880690-3	2003	Insulin-sensitizing agents may have greater effects in reducing cardiovascular risk than secretagogues in the pre-diabetic state, and glitazones have been found to decrease CRP levels in patients with diabetes.	Thiazolidinediones	134-144	C-reactive protein	Homo sapiens	173-176	
15959408-6	2005	Thiazolidinediones decrease plasma levels of C reactive protein, possess antiinflammatory effects through a reduction of inflammatory cytokines production, decrease free fatty acids levels, antagonize angiotensin II effects, increase adiponectin expression and production, etc.	Thiazolidinediones	0-18	C-reactive protein	Homo sapiens	45-63	
14693409-1	2004	Insulin-sensitizing thiazolidinediones (TZDs) decrease inflammatory markers such as high-sensitive C-reactive protein (hsCRP) in sera in addition to their hypoglycemic effects.	Thiazolidinediones	20-38	C-reactive protein	Homo sapiens	99-117	
14693409-1	2004	Insulin-sensitizing thiazolidinediones (TZDs) decrease inflammatory markers such as high-sensitive C-reactive protein (hsCRP) in sera in addition to their hypoglycemic effects.	Thiazolidinediones	40-44	C-reactive protein	Homo sapiens	99-117